Loading
companiesCompany
Compass Therapeutics
Compass makes antibodies that hit two targets at once to reshape the blood supply and immune environment of tumours. Its lead drug, tovecimig, blocks two blood-vessel growth signals and is heading for a possible US approval filing in bile duct cancer.
Overview
Compass Therapeutics is a Boston clinical-stage, oncology-focused company developing antibody-based therapeutics. Lead candidate tovecimig is a DLL4 x VEGF-A bispecific antibody; data from the COMPANION-002 phase 2/3 study in biliary tract cancer were selected for an oral presentation at ESMO 2026, and the company expects FDA feedback in the third quarter of 2026 ahead of a potential BLA filing later in the year. CTX-8371, a PD-1 x PD-L1 bispecific, is in phase 1 cohort expansions in triple-negative breast cancer, Hodgkin lymphoma and non-small cell lung cancer, and CTX-10726, a PD-1 x VEGF-A bispecific, has dosed its first phase 1 patients with initial data expected in the fourth quarter of 2026. A phase 2 study of CTX-471, a CD137 agonist antibody, in NCAM (CD56)-expressing tumours is planned. Compass had $180 million in cash and marketable securities at 30 June 2026, expected to fund operations into 2028. Nasdaq: CMPX.
Headquarters
Boston, MA, US
Scorecard
All companies#369of 1244 companies, score 10
- phase 3 +3
- targets +2
- modalities +2
- registry trials +3
0 approved, 1 in phase 3, 0 earlier, 1 targets, 2 registry studies. Formula on the scorecards page.
Type
Biotech · CMPX
Stage
Public
Website
Phase 3bispecific antibody
Tovecimig is an experimental bispecific antibody from Compass Therapeutics in phase 3 trials for biliary tract cancer and bladder & urothelial cancer, aimed at VEGF / VEGFR.
Notes
top- No funding round sourced.
Similar pages
- CompanyOnc.AI
Shares PD-L1, PD-1, Immune checkpoint inhibitors, Non-small-cell lung cancer.
- TrialA Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) With Acquired Resistance to Immunotherapy and Hig
Shares Bispecific antibodies, Anti-angiogenic therapy, Immune checkpoint inhibitors, Non-small-cell lung cancer.
- TrialAK112 in Non-squamous Non-small Cell Lung Cancer (NSCLC)Patients With Actionable Genomic Alterations (AGA) Who Have Failed to Previous Tyrosine Kinase Inhibitor
Shares Bispecific antibodies, Anti-angiogenic therapy, Immune checkpoint inhibitors, Non-small-cell lung cancer.
- TrialSEVILLA
Shares VEGF / VEGFR, Bispecific antibodies, PD-1, Biliary tract cancer (cholangiocarcinoma).
- PersonBrian I. Rini
Shares VEGF / VEGFR, Anti-angiogenic therapy, PD-1, Immune checkpoint inhibitors.
- TrialEA2197 ivonescimab: ivonescimab with gemcitabine and cisplatin versus standard chemo-immunotherapy in advanced biliary tract cancer
Shares VEGF / VEGFR, Bispecific antibodies, PD-1, Biliary tract cancer (cholangiocarcinoma).
- TrialA Study of Ivonescimab, Chemotherapy, and Stereotactic Radiosurgery for People With Non-Small Cell Lung Cancer
Shares Bispecific antibodies, Anti-angiogenic therapy, Immune checkpoint inhibitors, Non-small-cell lung cancer.
- TrialctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)
Shares Bispecific antibodies, Anti-angiogenic therapy, Immune checkpoint inhibitors, Non-small-cell lung cancer.
cancers
fronts
technologies
targets
drugs
Phase 3bispecific antibody